SCHEMBL3045105

SCHEMBL3045105

C=CCN(C)Cc1cc(-c2ccnc(Nc3cccc(N)c3)n2)ccc1OC

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK5 Q00535 2/20 0.58
MEN1 O00255 1/20 0.51
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
KMT2A Q03164 1/20 0.51
CDK5R1 Q15078 1/20 0.51
ABL1 P00519 3/20 0.50
BCR P11274 3/20 0.50
JAK2 O60674 3/20 0.50
SRC P12931 2/20 0.50
FLT3 P36888 1/20 0.50
EGFR P00533 3/20 0.48
PRKACA P17612 1/20 0.48
PRKACG P22612 1/20 0.48
PRKACB P22694 1/20 0.48
CAMK2D Q13557 1/20 0.48
PIK3CG P48736 6/20 0.46
PIK3CA P42336 5/20 0.46
PIK3CB P42338 4/20 0.46
PLK1 P53350 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3045102 0.88 JAK2 (0.49) CDK5ABL1BCRJAK2SRC
SCHEMBL823934 0.84 ABL1 (0.47) ABL1BCRJAK2SRCFLT3
SCHEMBL4901211 0.81 CDK5 (0.75) CDK5MEN1NPC1RAB9AKMT2A
SCHEMBL12801118 0.80 CDK5 (0.73) CDK5MEN1NPC1RAB9AKMT2A
SCHEMBL824010 0.77 KMO (0.41) MEN1KMT2AJAK2EGFRPIK3CG
SCHEMBL824003 0.77 ABL1 (0.42) ABL1BCRJAK2FLT3EGFR
SCHEMBL14530985 0.76 ALDH1A1 (0.39) MEN1NPC1RAB9AKMT2AJAK2
SCHEMBL12274536 0.76 CDK5 (0.67) CDK5MEN1NPC1RAB9AKMT2A
SCHEMBL824072 0.73 PIK3CA (0.44) ABL1BCRJAK2SRCFLT3
SCHEMBL4903233 0.73 JAK2 (0.65) CDK5MEN1NPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9133214-B2 Heteroalkyl linked pyrimidine derivatives S*BIO PTE LTD (SG) 2015-09-15 US disclosed
US-20120142680-A1 HETEROALKYL LINKED PYRIMIDINE DERIVATIVES S*BIO PTE LTD. (SG) 2012-06-07 US disclosed
EP-1951730-B1 HETEROALKYL LINKED PYRIMIDINE DERIVATIVES S BIO PTE LTD (SG) 2010-05-26 EP disclosed
US-20090258886-A1 HETEROALKYL LINKED PYRIMIDINE DERIVATIVES S*BIO PTE LTD. (SG) 2009-10-15 US disclosed
EP-1951730-A1 HETEROALKYL LINKED PYRIMIDINE DERIVATIVES S*Bio Pte Ltd (SG) 2008-08-06 EP disclosed
WO-2007058628-A1 HETEROALKYL LINKED PYRIMIDINE DERIVATIVES S*BIO PTE LTD (SG) 2007-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258886-A1 HETEROALKYL LINKED PYRIMIDINE DERIVATIVES TK1, TK2, DPYD CDK5 45/4885MEN1 3900/4885NPC1 2644/4885
US-20120142680-A1 HETEROALKYL LINKED PYRIMIDINE DERIVATIVES TK1, TK2, DPYD CDK5 45/4885MEN1 3900/4885NPC1 2644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.